Good mobilization is essential for PBSC collection with a minimum number of aphereses. Mobilization failures and repeated apheresis sessions are particularly undesirable in children, as they usually require central venous accesses which cause discomfort and can be complicated with infection if carried for a long period of time while trying new mobilization schemes. Also, repeated and prolonged apheresis sessions are not well tolerated by children.
It is therefore of great interest to develop mobilization schemes for children that ensure PBSC collections with a minimum number of aphereses. Also, as double or triple transplants are increasingly been used in children, it is often necessary to obtain great numbers of PBSC. It would be desirable to obtain them with only one apheresis session.
There is some evidence suggesting that increased doses of granulocyte colony-stimulating factor (G-CSF) have greater mobilization potential than standard ones.
1,2 A recent study in children showed that high doses produced higher CD34 peak values than standard ones although they did not reduce the number of leukaphereses. 3 However, the G-CSF was administered in a single daily dose, whilst there is evidence that dividing the total daily dose in two 12-h fractions results in higher CD34 yields and fewer apheresis procedures. 4 We evaluated the safety and efficacy of high dose (24 g/kg) 12-h divided G-CSF for mobilization in children. Twenty-three consecutive patients submitted to our bone marrow transplant unit for autologous PBSC transplant were mobilized with rhG-CSF (filgrastim). All patients had been intensively treated prior to PBSC transplantation. Filgrastim was given at 24 g/kg/day divided in two 12-h doses. The first 16 patients received G-CSF for 4 days, and the rest for 3 days. On the 5th or 4th day respectively, patients were given the morning dose of G-CSF and the CD34 + cell count was determined in a Dako Gakaxy flow cytometer according to ISHAGE protocol. Patients with CD34 counts у15 ϫ 10 6 /l were submitted to a large volume leukapheresis (LVL) with the Cobe Spectra AutoPBSC procedure, aimed to obtain at least 2 ϫ 10 6 CD34/kg.
Patients' characteristics, WBC, platelet and CD34 + cell counts on the day of apheresis and the CD34 + cell content of the apheresis product are shown in Table 1 . Eighteen patients (78.26%) attained CD34 + cell counts equal or greater than 15 ϫ 10 6 /l and were submitted to LVL. The target dose of CD34 + cells was achieved with one single apheresis in all patients (median CD34/kg: 3.88 ϫ 10 6 , range 1.9 to 12.7). One patient had an intermediate mobilization, with a CD34 + cell count of 12.64 ϫ 10 6 /l and needed two aphereses to obtain sufficient CD34 cells.
The mobilization failed in four patients. Two of these patients (both with osteosarcoma) subsequently failed to mobilize with two different combinations of chemotherapy and G-CSF and finally underwent bone marrow aspiration. The two other failing patients were satisfactorily mobilized with cyclophosphamide (1.5 g/m 2 ) and G-CSF (12 g/kg/day).
The patients reported no clinical side-effects with this high-dose G-CSF schedule. Two patients developed leukocytosis greater than 100 ϫ 10 9 /l. However, no clinical symptoms attributable to this degree of leukocytosis were present. Four additional patients developed mild thrombocytopenia (platelet count 63 to 114 ϫ 10 9 /l) that could not be attributed to other causes.
In conclusion, high-dose G-CSF is well tolerated by children, and in combination with large volume leukapheresis it allows PBSC collection with a single apheresis in heavily treated patients. The benefit and cost-effectiveness of high versus standard G-CSF doses for mobilization in children should be tested in a randomized study. 
